Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
ZYUS Life Sciences ( (TSE:ZYUS) ) just unveiled an update.
ZYUS Life Sciences Corporation has announced the issuance of bonus warrants to independent directors as part of loan agreements, following conditional acceptance from the TSX Venture Exchange. These warrants are linked to the extension and amendment of unsecured loans and a promissory note agreement, which have been converted into new loan agreements with extended maturity dates. This move is part of ZYUS’s strategy to strengthen its financial position and enhance shareholder value, while also navigating regulatory requirements for related party transactions.
More about ZYUS Life Sciences
ZYUS Life Sciences Corporation is a Canadian-based life sciences company specializing in the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates aimed at pain management. The company focuses on securing intellectual property protection and obtaining regulatory approval for non-opioid-based pharmaceutical solutions to make a transformational impact on patients’ lives.
YTD Price Performance: -15.38%
Average Trading Volume: 8,598
Technical Sentiment Signal: Strong Buy
Current Market Cap: C$45.11M
Learn more about ZYUS stock on TipRanks’ Stock Analysis page.